A Phase II Pilot Study of yttriuM-90 in Combination With capEcitabine and aTezolizumab for oligomEtastatic cOlorectal Cancer With unResectable lIver MeTastasEs (METEORITE)

BrUOG-430 is a prospective, single-arm, phase 2 trial evaluating yttrium-90 radioembolization in combination with capecitabine and atezolizumab for the treatment of unresectable colorectal cancer liver metastases in individuals who have been treated with two or more lines of systemic therapy.

开始日期2025-04-07

申办/合作机构

Brown University

[+2]

NCT06725121

/ Recruiting临床1/2期IIT

Downstaging of Hepatocellular Carcinoma with Macrovascular Invasion by Radiotherapy (SBRT or Y90) and Atezolizumab Plus Bevacizumab Followed by Liver Transplantation - a Prospective Trial

The goal of this clinical trial is to learn if locoregional therapy and immunotherapy can be used together to help patients with hepatocellular carcinoma (HCC) and macrovascular invasion achieve liver transplantation.
The main questions it aims to answer are:
* How many patients will achieve transplant with this treatment strategy?
* What will the 5-year survival and recurrence-free survival rates be for these patients?
Participants will:
* Undergo a biopsy of the tumor.
* Receive locoregional therapy (SBRT or Y90) followed by immunotherapy (atezolizumab and bevacizumab) 2 to 6 weeks later, for a maximum of 9 months.
* Be referred for a liver transplant and undergo the procedure if deemed eligible and safe.
* If applicable, be followed for five years post-transplant with regular data collection.

开始日期2024-12-01

申办/合作机构

University Health Network

NCT05655949

/ Recruiting临床2期IIT

A Single Arm Phase 2 Study of Y-90 SIRT in Combination with Durvalumab (MEDI 4736) and Gemcitabine/cisplatin in Locally Advanced, Unresectable or Metastatic Intrahepatic Cholangiocarcinoma

This trial is designed to study a combination of interventions (chemotherapy, immunotherapy, and radiation) as a potential new treatment for bile duct cancer that cannot be removed with surgery.
The specific names of the interventions that will be used are:
* Y-90 (a type of radiation microsphere bead)
* Durvalumab (a type of immunotherapy)
* Gemcitabine (a type of chemotherapy)
* Cisplatin (a type of chemotherapy)

开始日期2024-02-13

申办/合作机构

Beth Israel Deaconess Medical Center, Inc.

[+3]

100 项与钇90 相关的临床结果

登录后查看更多信息

100 项与钇90 相关的转化医学

登录后查看更多信息

100 项与钇90 相关的专利（医药）

登录后查看更多信息

4,741

项与钇90 相关的文献（医药）

2025-09-01·RADIATION PHYSICS AND CHEMISTRY

Implementation of dosimetry in molecularradiotherapy in Spain. Results from a Spanish survey

作者: Cerrato, Celia ; Moya, Estrella ; Bedoya, Luis Miguel ; Guerra, Jose Antonio

The implementation of the dosimetry and optimization requirements for radiopharmaceuticals of therapy, established in the Euratom Safety Standards Directive (EC Directive 2013/59/Euratom), is a major challenge in European countries.The aim of this study is to evaluate the current practice in mol. radiotherapy (MRT) in Spain.An electronic questionnaire has been distributed to Spanish Nuclear Medicine Departments (NMDs) in order to have an overview of the current situation with regard to the optimization of radiopharmaceutical therapies and the anal. of the resources available in hospitals.This survey received 24 replies, which represents 16 % of the total number of Spanish NMDs geog. distributed over 17 Spanish Autonomous communities.A Quality Assurance Program (QAP) has been developed in 96 % of Spanish NMDs that replied to the survey, and 86 % of these QAPs include the criteria for justifying medical exposure.Regarding staff knowledge of the provisions of Directive 2013/59/Euratom, 70 % of the responses were pos.A high level of compliance with the Summary of Product Characteristics for each therapy was observed in relation to the officially approved conditions of use of radiopharmaceutical therapies.Planning of the activity to administer with physician involvement is used only for non-standardized procedures (70 %).However, non-standardized procedures do not seem to be common practice.The use of activities based on fixed-activity protocols is more than 82 % for all therapies, except for the radiopharmaceutical I-131 MIBG (56 %).As regards the assessment of the resources available to carry out dosimetry-guided treatments, only 4 % considered them to be adequate.Patient-specific dosimetry has not yet been implemented in Spanish NMDs as a daily routine due to the lack of resources, training and specific regulatory instructions to perform it.

2025-07-01·SEPARATION AND PURIFICATION TECHNOLOGY

Highly efficient separation of yttrium from concentrated strontium aqueous solution by novel silica-based HDEHP-impregnating adsorbent

作者: Wei, Yuezhou ; Sun, Jiayu ; Wu, Qiang ; Zeng, Deqian ; Wu, Yehuizi ; Jiang, Tianjiao ; Ning, Shunyan ; Watabe, Hiroshi ; Yin, Xiangbiao ; Hamza, Mohammed F. ; Zheng, Ningchao ; Wang, Fan ; Zheng, Qi ; Wu, Hao ; Wu, Yan

As the primary fission product in spent nuclear fuel being generally filed into the high-level liquid waste, the ⁹⁰Sr recovered from the reprocessed nuclear fuel could be a significant source for producing ⁹⁰Y nuclide (the decay daughter).It presents as one favorable therapeutic radionuclide candidate for radiolabeling of pharmaceuticals in widespread clin. application.Under this situation, a novel silica-based adsorbent (HDEHP/SiO₂-P) was developed for selective separation of Y³⁺ from concentrated Sr²⁺ in aqueous solutionBatch adsorption process was investigated under different parameters of acid type and strength, contact time, temperature, ionic concentration and molar ratio etc.It was confirmed that, the HDEHP/SiO₂-P had highly selective properties toward Y³⁺ over Sr²⁺ in different acidic medium (i.e., hydrochloric, nitric and acetic acid), with maximum adsorption capacity 34.05 mg Y³⁺/g.Sorption isotherms and uptake kinetics, were better fitting for Langmuir monomol. layer adsorption mode and the pseudo-second order (PSORE) kinetic model resp.The sorbent shows high SF_Y/Sr of 1.93 x 10³ even at a Sr-Y molar ratio of 2 x 10³.Moreover, dynamic separation of trace amount of Y³⁺ from the concentrated Sr²⁺ aqueous solution was successfully validated by the column test, in which 100 % Y³⁺ was recovered.The produced eluate is characterized by a sharp elution curve without Sr trailing under high acidic conditions of 6 M HCl.All these results would promisingly promote the application of the developed material and chromatog. approach to facilely obtain the adequate quantities of ⁹⁰Y with required radiochem. purity for its widespread clin. use.

2025-06-01·MARINE POLLUTION BULLETIN

Analysis and prediction of the impact of Fukushima nuclear polluted water on the Chinese sea area

Article

作者: Wang, Fenfen ; Zheng, Guohua ; Men, Wu ; Zhou, Gexinyan ; Liu, Quandi

Discharge of Fukushima nuclear polluted water (NPW) into the ocean has aroused a new round of public concern. Based on the previous research findings and the data released by Japan, this work discusses transport of NPW in the North Pacific Ocean, the time required for NPW to reach the Chinese Sea area, variations in activity concentrations, and radiation effects on the marine organisms to predict the NPW's impact on the Chinese sea area. It reveals that the amount of NPW are transported to the Chinese sea area under the combined action of mode waters and mesoscale eddies with a transit period of 2-3 years. The corresponding amount is dominated by the strength of Kuroshio-Kuroshio Extension system. The increases of the ¹³⁷Cs, ⁹⁰Sr and ³H in the Chinese sea area will be indistinctive and covered in the fluctuations of their backgrounds. The other nuclides (⁶⁰Co, ⁹⁰Y, ⁹⁹Tc, ¹²⁵Sb, ^125mTe, ¹²⁹I) derived from NPW will be diluted to be negligible. Such low level of radioactivity is insufficient to cause‌ radiation effects ‌on‌ marine organisms. Given the limitations of this prediction, it is imperative to implement regular monitoring and validate the impacts through actual observational data.

项与钇90 相关的新闻（医药）

2025-03-24

·PRNewswire

Actinium Pharmaceuticals Announces Supply Agreement with Eckert & Ziegler for Ac-225 Radioisotope to Support Comprehensive Development Activities

NEW YORK, March 24, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced it has entered into an agreement for the supply of Actinium-225 (Ac-225) with Eckert & Ziegler. Under this agreement, Actinium Pharmaceuticals will have access to Eckert & Ziegler's high-quality Actinium-225 to further develop its lead product Actimab-A as well as additional early and late-stage development candidates for both U.S. and international clinical trials. Targeted radiotherapies using Ac-225 have shown great promise in the treatment of cancer. The radioisotope releases powerful alpha particles with high energy and low penetration depth, enabling precise targeting of tumor cells, including hard-to-reach micrometastases, while minimizing effects on surrounding healthy tissue. Actimab-A is an Ac-225 based radiotherapy agent, directed against CD33, a receptor overexpressed in patients with acute myeloid leukemia (AML) and other myeloid indications. Sandesh Seth, Chairman and CEO at Actium Pharmaceuticals, Inc. commented: "We believe that targeted radiation therapy with Actinium-225 is one of the most promising approaches for treating patients with myeloid malignancies and solid tumors. As we have highlighted recently, we are advancing our lead targeted radiotherapy Actimab-A into a pivotal Phase 2/3 trial for patients with relapsed or refractory acute myeloid leukemia and in the frontline setting in a Phase 1 trial under our CRADA with the NCI. Additionally, we have launched our Actimab-A solid tumor program to combine with PD-1 checkpoint inhibitors KEYTRUDA and OPDIVO for patients with head and neck squamous carcinoma and non-small cell lung cancer in multiple trials. As a pioneer in the development of target radiotherapies, we have aggressive plans to expand our clinical pipeline to address indications with high unmet needs. With this supply agreement with Eckert & Ziegler, we will have access to reliable and constant supply of Ac-225 to advance our product development both in the U.S. as well as internationally." "We are happy to contribute to the continuous expansion of indications for Actinium-225, which is significantly being advanced by Actinium Pharmaceuticals," explained Dr. Harald Hasselmann, CEO of Eckert & Ziegler SE. "The progress we have made in our Ac-225 project over the past year marks only the start of our program to address the global shortage of this vital radionuclide." Eckert & Ziegler reliably supplies high-quality Gallium-68, Lutetium-177, Yttrium-90, and Actinium-225 to leading pharmaceutical companies, and research institutions worldwide. With expertise in radioisotope production and global logistics, the company is committed to continuously support the development and delivery of innovative radiopharmaceuticals. About Eckert & Ziegler Eckert & Ziegler SE, with more than 1,000 employees, is a leading specialist in isotope-related components for nuclear medicine and radiation therapy. The company offers a broad range of services and products for the radiopharmaceutical industry, from early development work to contract manufacturing and distribution. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche Börse. Contributing to saving lives. About Actinium Pharmaceuticals, Inc. Actinium is a pioneer in the development of targeted radiotherapies intended to meaningfully improve patient outcomes. Actinium is advancing its lead product candidate Actimab-A, a CD33 targeting therapeutic, as potential backbone therapy in acute myeloid leukemia (AML) and other myeloid malignancies leveraging the mutation agnostic alpha-emitter radioisotope payload Actinium-225 (Ac-225). Actimab-A has demonstrated potential activity in relapsed and refractory acute myeloid leukemia (r/r AML) patients in combination with the chemotherapy CLAG-M including high rates of Complete Remissions (CR) and measurable residual disease (MRD) negativity leading to improved survival outcomes and is being advanced to a pivotal Phase 2/3 trial. In addition, Actinium is engaged with the National Cancer Institute (NCI) under the Cooperative Research and Development Agreement (CRADA) for development of Actimab-A in AML and other myeloid malignancies. The first clinical trial under the CRADA will evaluate the triplet combination comprised of Actimab-A, Venetoclax (Abbvie/Roche) an oral Bcl-2 inhibitor and ASTX-727 (Taiho Oncology, an Otsuka holdings company) a novel oral hypomethylating agent (HMA) in frontline acute myeloid leukemia (AML) patients. Additionally, Actinium is developing Actimab-A as a potential pan tumor therapy in combination with PD-1 checkpoint inhibitors including KEYTRUDA® and OPDIVO® by depleting myeloid derived suppressor cells (MDSCs), which represents a potential multi-billion-dollar addressable market. Iomab-ACT, Actinium's next generation conditioning candidate, is being developed with the goal of improving patient access and outcomes for potentially curative cell and gene therapies. Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with r/r AML, which Actinium is seeking a potential strategic partner for the U.S. In addition, the company's R&D efforts are primarily focused on advancing several preclinical programs for solid tumor indications. Actinium holds 230 patents and patent applications including several patents related to the manufacture of the isotope Ac-225 in a cyclotron. For more information, please visit: Forward-Looking Statements This press release may contain projections or other "forward-looking statements" within the meaning of the "safe-harbor" provisions of the private securities litigation reform act of 1995 regarding future events or the future financial performance of the Company which the Company undertakes no obligation to update. These statements are based on management's current expectations and are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with preliminary study results varying from final results, estimates of potential markets for drugs under development, clinical trials, actions by the FDA and other governmental agencies, regulatory clearances, responses to regulatory matters, the market demand for and acceptance of Actinium's products and services, performance of clinical research organizations and other risks detailed from time to time in Actinium's filings with the Securities and Exchange Commission (the "SEC"), including without limitation its most recent annual report on form 10-K, subsequent quarterly reports on Forms 10-Q and Forms 8-K, each as amended and supplemented from time to time. Investors: [email protected] SOURCE Actinium Pharmaceuticals, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

放射疗法

2025-03-23

·ioncology

澳领新肝线丨韩国宏教授、杨正强教授共话肝病介入治疗的围术期血小板管理之道

点击蓝字关注我们肝病相关血小板减少症（HRT）是临床实践中的常见挑战之一，尤其对于需接受择期手术或侵入性操作的患者，血小板计数不足不仅显著增加围术期出血风险，更可能治疗计划延期甚至取消，严重威胁患者生命安全。鉴于血小板生成素（TPO）减少是HRT的核心机制，重组人血小板生成素（rhTPO）在治疗体系中展现出独特的应用价值。“全国爱肝日”期间，《国际肝病》特策划“澳领新肝线”栏目，首期邀请到西安国际医学中心医院韩国宏教授、中国医学科学院肿瘤医院杨正强教授，围绕肝病介入治疗的围术期血小板管理及治疗要点展开深入对话，为肝病患者的临床管理提供切实可行的建议。《国际肝病》近年来，介入治疗技术不断革新，钇-90树脂微球、现代TACE等精准介入技术相继应用于临床，肝病介入领域逐渐从‘技术突破’向‘系统优化’阶段演进，您认为这一改变对围术期管理提出了哪些新的标准和要求？韩国宏教授近年来，肝癌介入治疗领域取得了显著进展，为临床介入医师提供了更为精准、安全的治疗手段。其中，2021年我国引入的钇-90树脂微球选择性内放射治疗（⁹⁰Y-SIRT）具有里程碑意义。该技术通过β射线近距离持续释放，在实现高效杀灭肿瘤细胞的同时，对周围正常肝组织形成有效保护，并在肝细胞癌及肝转移癌的降期转化、门静脉癌栓控制等方面展现出显著优势1-3。2024年《钇-90微球选择性内放射治疗肝脏恶性肿瘤规范化操作专家共识》的发布4，为我国临床实践提供了更为明确的技术指导，标志着我国该领域进入标准化发展阶段。现代介入技术革新则呈现多维度创新态势，以药物洗脱微球经导管动脉化疗栓塞（DEB-TACE）、锥形束CT（CBCT）影像引导技术为核心，结合桡动脉入路等新型操作路径，形成多领域协同发展的技术生态，极大地拓展了介入治疗的临床应用边界5-7。此外，以多模态影像导航联合复合式冷热消融系统为代表的技术融合创新8-9，正引领现代介入治疗迈向新的高度。这些进展共同推动肝癌等肝病的治疗从经验决策向量化模型支持的精准医疗转型。技术革新与靶向免疫治疗的协同应用，也成为肝癌综合治疗领域的重要研究方向。在介入体系向系统化方向演进的时代背景下，围手术期管理标准亟待提升，尤其在出血风险控制和血小板管理方面，需建立更精细化的标准体系。鉴于肝病患者普遍存在的血小板减少问题，需建立包括药物干预、成分输血在内的分层管理方案，通过动态监测优化围术期血小板管理决策。以钇-90微球治疗为例，应严格把控术前评估、术中操作及术后放射性损伤管理，包括放射性肝损伤引起的血小板减少等并发症1。如何在药物选择、介入操作与出血风险之间找到平衡，已成为介入医师必须深入考虑的临床课题。《国际肝病》您参与编撰了《靶向免疫联合局部治疗中晚期肝细胞癌中国专家共识》，其中提到了靶免联合局部治疗时需重点关注的要点包括血小板下降。请问您认为应如何评估合并血小板减少的肝癌患者在介入治疗期间的出血风险？更进一步来看，肝病相关血小板减少症相应的管理策略有哪些？杨正强教授由中国医学科学院肿瘤医院蔡建强教授、北京协和医院赵海涛教授等专家共同牵头制定的《靶免联合局部治疗中晚期肝细胞癌中国专家共识》（以下简称“共识”），规范了临床实践中诊疗及并发症管理策略10。其中在靶向-免疫联合局部治疗"三靶联合"的背景下，血小板减少管理成为重要议题之一。在肝癌患者中，高达80%的肝癌患者合并肝硬化，而肝硬化人群中约78%存在血小板减少症11。其病理机制主要包括两方面：首先，肝损伤导致血小板生成素（TPO）合成减少，作为巨核细胞分化及血小板生成的关键调节因子，其水平下降直接影响血小板生成12；其次，门静脉高压引发的脾功能亢进促使血小板在脾脏血管池内滞留增加13。血小板减少的病理状态与"三靶联合"治疗模式叠加，可能加剧血小板减少，成为影响治疗连续性和安全性的重要因素。此外，在慢性肝病的诊疗中，同样需充分认识到肝病相关血小板减少症的高发性。无论是肝硬化还是肝炎，均会对血小板生成素的合成造成影响，进而引发血小板减少。因此，临床工作中应对此给予足够重视，同时充分考虑血小板减少对各类医疗操作的影响，若未加以重视，极有可能引发严重后果。该共识中血小板减少症的分级标准如下：1级的血小板计数范围为≥75×10⁹/L～＜100×10⁹/L；2级≥50×10⁹/L～＜75×10⁹/L；3级≥25×10⁹/L～＜50×10⁹/L；4级＜25×10⁹/L。对于1～2级血小板下降且无出血倾向者，可持续监测观察，考虑使用重组人血小板生成素（rhTPO）等TPO类药物；3～4级血小板下降或血小板持续不恢复者，应筛查其他原因对症处理，同时积极升板治疗10。由解放军总医院第五医学中心王福生院士主导制定的《肝病相关血小板减少症临床管理中国专家共识》指出，血小板计数≥50×10⁹/L是常见的干预目标值，推荐TACE、消融、肝动脉灌注化疗（HAIC）、经颈静脉肝内门体分流术（TIPS）等操作的血小板计数参考阈值达≥50×10⁹/L，而针对新兴的钇-90树脂微球选择性内放射治疗，因其可能引发放射性肝损伤导致血小板进一步下降，建议将术前血小板阈值提升至≥80×10⁹/L11。在肝病管理工作中，血小板减少症虽常被视为伴随症状，然而它实则是治疗过程中的“限速性因素”，并且有相当一部分患者血小板水平难以维持在稳定状态，极有可能致使治疗受到阻碍，或者引发严重的出血并发症。由此可见，强化血小板管理对于确保治疗的安全性以及提升治疗效果而言，具有至关重要的意义。值此“全国爱肝日”这一特殊时刻，我们期望能够进一步提高广大临床工作者对血小板管理的重视程度，推动进一步优化肝病患者综合治疗方案，从而为患者的健康提供更坚实有力的保障。《国际肝病》您在为择期介入治疗的肝病患者制定升板方案时，您通常会考虑哪些因素？您如何看待血小板输注、有创治疗等升板手段在高要求的介入围术期管理中的局限性，例如在升板持续性和可及性等方面？韩国宏教授肝病患者的凝血系统呈现“再平衡”状态，具体表现为促凝因子水平升高与抗凝因子水平减少同时存在，血小板减少与血小板功能异常相互叠加14-15。在制定升板方案时，需要充分考虑止血与抗栓之间的平衡，避免过度干预。这就要求综合考量患者的个人期望与个体情况、凝血指标、即将进行的操作类型及时间、出血风险等多种因素，同时将不同升板治疗方法的优缺点纳入评估范围。对于临床医生高度关注的升板治疗策略，深入且细致地了解并评估不同治疗手段的优缺点至关重要。针对血小板输注这一传统干预手段，既往研究显示，肝病患者术前输注1 U血小板术后24小时血小板计数提升约10×10⁹/L16。然而，血小板输注提升效果在慢性肝病患者中难以持久——即使达到50×10⁹/L阈值，其维持时间通常不超过48小时17。值得关注的是，部分患者在连续≥2次接受足够剂量血小板输注后，会出现血小板计数未达预期或出血症状未改善等血小板输注无效（PTR）的情况，并可能伴随发热及过敏反应等不良反应11,18。鉴于血小板保存期短、临床供应紧缺及潜在输注风险等因素，建议血小板输注仅用于有危及生命出血风险及需接受紧急手术的患者11。尽管部分有创治疗可维持较长时间的血小板计数，但操作本身需满足特定血小板阈值要求，且术后静脉血栓的发生率显著增高，需权衡利弊，谨慎选择。因此，临床亟需探索更为安全有效的替代治疗方案，如持续升板且低血栓风险的促血小板生成类药物。其中，针对肝病患者TPO生成不足的病理机制，rhTPO可通过外源性补充实现持续升板，为择期介入治疗提供了安全有效的护航方案。《国际肝病》 TPO有着准确的信号通路调节作用，研究显示其在肝病相关血小板减少症中起到重要作用。对于拟择期行介入治疗且血小板减少的肝病患者，例如肝癌患者，rhTPO加入治疗体系对综合管理有何意义？杨正强教授从作用机制层面来看，在促进血小板生成的药物体系中，TPO作为核心细胞因子，因其作用于巨核细胞分化、成熟及血小板释放的全过程调控特性，展现出更为平稳且持久的升板效应11。与内源性TPO结构高度一致的rhTPO，可针对肝病患者发挥外源性补充作用11，研究显示rhTPO治疗肝病相关血小板减少症可显著提升血小板计数，减少出血风险及降低血小板输注率19-20。最新研究显示，rhTPO可缓解辐射引起的造血祖细胞克隆形成和造血重建能力的降低，并维持造血干细胞的自我更新能力，改善急性骨髓抑制和长期骨髓损伤21。值得注意的是，随着靶免与介入结合应用日益增多，肿瘤治疗相关血小板减少（CTIT）的问题在围术期也不容忽视。相关《共识》指出10,22,23，rhTPO可以减轻CTIT患者血小板计数下降的程度，减少血小板减少持续时间和血小板输注次数。此外，血小板功能不仅限于止血系统调节，在脓毒症等感染性疾病中，其免疫调节作用及过度消耗问题需引起临床关注24。此时应用TPO受体激动剂可能获益欠佳，而rhTPO可更安全地纠正消耗性血小板减少。血小板管理所涉及的机制极为复杂，这就要求在诊疗过程中，精准制定并实施正确的管理策略。鉴于不同专业领域之间可能存在着一定的认知差异，因此，有必要加大宣讲力度并开展相关研讨活动，促使各方人员能够从病理机制以及临床多样化的应用场景出发，作出科学合理的诊疗决策。《国际肝病》如何把握介入治疗时机与血小板水平的平衡，以进一步提高肝病患者介入治疗的安全性和有效性？在肝病相关出血的治疗方面，您认为未来有哪些研究方向或潜在的策略值得期待？韩国宏教授在肝病患者的介入治疗过程中，构建个体化评估体系对于制定精准的围术期管理策略至关重要。术前充分评估患者状态，同时动态监测实验室检查指标变化情况，合理调整升板治疗策略，从而精准判断介入治疗的最佳时机。对于肝癌患者，在靶免联合局部治疗时代，介入时机需与系统治疗周期进行有序的整合，以最大程度地发挥协同效应，同时将不良反应降至最低。展望未来，肝病相关出血治疗领域或将聚焦于精准医学与人工智能的深度融合。智能化管理策略不仅能优化介入治疗的时机选择，还能为个体化抗凝/止血方案制定提供科学依据。在药物方面，TPO在肝再生/肝保护领域展现出独特的治疗潜力。日本的一项动物实验研究显示25，TPO有助于细胞周期进展和代谢途径，有望通过肝保护作用为患者取得潜在获益。我国团队相关研究提示rhTPO能够在有效提升血小板的同时，减少出血事件的发生，促进肝功能的改善26。基于相关研究，未来可进一步探索rhTPO肝保护作用在肝病相关出血领域以及肝病介入围术期的应用价值。总之，降维与分化是医学发展的内在力量，而升维与整合则是医学发展的必然方向，肝病介入领域亦不例外。为迈入“精准-微创-全程”的新阶段，肝病介入领域的围术期管理需同步实现动态化监测、个体化干预与多学科融合，从而为患者提供更加优质、高效的医疗服务。参考文献：（上下滑动查看更多） 1. 张琳,冯晓彬,黄鑫,等.钇‑90微球选择性内放射治疗在肝癌降期转化移植中的应用进展[J].中华消化外科杂志,2024,23(12):1566-1570. 2. 中国抗癌协会肿瘤介入学专业委员会, 国家卫生健康委能力建设和继续教育中心介入医学专家委员会,宋莉,邹英华.钇90微球管理专家共识.[J].中国介入影像与治疗学2021;18:321-5. 3. Wang DS, Louie JD, Sze DY. Intra-arterial therapies for metastatic colorectal cancer. Semin Intervent Radiol 2013;30:12-20. 4. 中国医师协会介入医师分会临床诊疗指南专委会, 中国研究型医院学会肝胆胰外科专业委员会. 钇-90微球选择性内放射治疗肝脏恶性肿瘤规范化操作专家共识（2024版） [J] . 中华医学杂志, 2024, 104(7) : 486-498. 5. 中国抗癌协会肿瘤介入学专业委员会，药物洗脱微球治疗不可切除原发性肝癌的临床应用共识.[J].中华放射学杂志, 2022, 56(4): 349-355. 6. 中国医师协会介入医师分会临床诊疗指南专委会，锥形束CT应用于肝脏恶性肿瘤介入诊疗的专家共识.[J].中华放射学杂志, 2024, 58(6): 596-602. 7. 中国抗癌协会肝胆肿瘤整合护理专业委员会.经桡动脉入路肝癌介入治疗综合管理中国专家共识（2024版）[J].中华消化外科杂志,2024,23(4):527-535. 8. 中国抗癌协会肿瘤消融治疗专业委员会, 中国临床肿瘤学会肿瘤消融治疗专家委员会, 中国医师协会介入医师分会介入围手术学组. 复合式冷热消融治疗肝肿瘤围手术期管理专家共识[J]. 中华内科杂志, 2025, 64(2): 110-118. 9. 刘文瑛，欧阳再兴，朱剑华，等．多模态影像技术在精准肝癌肝切除中的应用[J/OL]．中华肝脏外科手术学电子杂志，2022，11(6)：574-579. 10. 中国医疗保健国际交流促进会肝脏肿瘤学分会，中国医疗保健国际交流促进会免疫学分会,等.靶向免疫联合局部治疗中晚期肝细胞癌中国专家共识[J].临床肝胆病杂志,2023,39(12):2782-2792. 11. 国家感染性疾病临床医学研究中心, 北京医学会肝病学分会, 中国老年学和老年医学学会转化医学分会.肝病相关血小板减少症临床管理中国专家共识[J]. 临床肝胆病杂志, 2023, 39(10): 2307-2320. 12. 李剑萍,谭颖,孙航,林淦秋,陈彬彬,吴跃,谢志伟,王亚萍,陆霭琪,关玉娟.肝硬化血小板减少症的临床管理[J].中华肝脏病杂志,2024,32(6):489-492. 13. 肖函，王利. 肝硬化血小板减少的病理生理发生机制[J]. 实用肝脏病杂志, 2019, 22(4):462-465. 14. 李雪,张亮,王枭,易海,汤善宏.凝血功能监测在慢加急性肝衰竭诊治中的相关研究进展[J].肝脏,2023,28(02):247-249. 15. 孙荣荣,贺娜,张粉娜,等.肝硬化凝血障碍机制的再认识[J].临床肝胆病杂志,2024,40(3):616-620. 16. 王淑英, 周文辉, 李新颖, 等. 肝病患者血小板输注情况调查分析[J]. 临床输血与检验, 2017, 19( 4): 328－331. 17. F Y, T H, Y Y, et al. Thrombopoietin receptor agonist is more effective than platelet transfusion for chronic liver disease with thrombocytopenia, shown by propensity score matching[J]. Hepatol Res, 2020, 50( 9): 1062－1070. 18. 温丽玲,余卓丽,梁惠兰,等.英国血小板输注应用指南主要推荐及其启示[J]. 中国输血杂志, 2018, 31( 4): 440－444. 19. FENG R, LIU Y, ZHU XL, et al. Recombinant human thrombopoietin increases platelet count in severe thrombocytopenic patients with hepatitis B－related cirrhosis: Multicentre real－world observational study[J]. J Viral Hepat, 2022, 29( 5): 306－316. 20. DING JN, FENG TT, SUN W, et al. Recombinant human thrombopoietin treatment in patients with chronic liver disease－related thrombocytopenia undergoing invasive procedures: A retrospective study[J]. World J Gastrointest Surg, 2022, 14( 11): 1260－1271. 21. LUAN H, YANG JK, WANG YM, et al. rhTPO ameliorates radiation-induced long-term hematopoietic stem cell injury in mice.Molecules.2023.28(4):1953. 22. 中国抗癌协会肿瘤临床化疗专业委员会，肿瘤支持治疗专业委员会等.中国肿瘤药物相关血小板减少诊疗专家共识（2023版）. 中华医学杂志, 2023,103(33): 2579-2590. 23. 中国临床肿瘤学会指南工作委员会组织编写. CSCO肿瘤治疗所致血小板减少症诊疗指南2024. 北京：人民卫生出版社. 2024 24. 脓毒症相关的血小板减少症临床诊疗中国专家共识专家组. 脓毒症相关的血小板减少症临床诊疗中国专家共识[J].中华重症医学电子杂志,2023,9(3):225-240. 25. Andriy M,et al, Joumal of Hepatology. 49 (2008)363-372. 26. 梁静.第33届亚太肝脏研究学会年会（APASL 2024）.No.101122 O-0839 &No.100364 O-0824 &No.100495 O-0863. 专家简介韩国宏教授主任医师、博士生导师西安国际医学中心消化病医院执行院长国际门静脉高压最权威Baveno Ⅶ 专家组成员、科学委员会委员亚太原发性肝癌理事会理事（APPLE Council Member）中国抗癌协会第九届理事会理事中国非公立医疗机构协会介入医学分会会长中国抗癌协会-中西医整合肝癌专委会主委中国抗癌协会-整合肝癌专委会和肿瘤肝病学专委会副主委中国研究型医院学会-介入专委会副主委卫健委原发性肝癌诊疗指南专委会介入治疗组副组长（2011版、2017版、2019版、2022版和2024版） 2023年、2024年入选全球2%顶尖科学家、2021年入选全球学者库 2020-2023年连续4年入选“中国高被引学者” 2020年中国消化病领域学术影响力排名TOP 100中位列第六 2017年以第一完成人获军队科技进步一等奖 2016年作为主要成员获国家科学进步奖创新团队奖 2011年以来作为第一或通讯作者在Nat Rev Gastro Hepatol、Ann Oncol、Lancet Gastro Hepatol、Gastroenterology、J Hepatol、Gut、Radiology等权威杂志发表SCI同行评议论文164篇。他引8000余次，H指数49 杨正强教授中国医学科学院肿瘤医院介入治疗科, 主任医师, 博导中国抗癌协会, 微创治疗专业委员会, 常委中国抗癌协会, 肿瘤消融专业委员会, 常委中国研究型医院学会, 消化外科专委会, 常委中国妇幼保健协会, 介入放射专委会, 常务委员中国中西医结合学会, 周围血管疾病静脉通路专委会, 副主任委员世界华人肿瘤医师协会，微创介入专业委员会，常务委员北京肿瘤学会, 介入治疗专委会, 秘书长国家药品监督管理局药品评价中心学术委员会，委员中华医学会放射学分会，胃肠道及胰腺疾病专委会，委员中华介入放射学杂志编委中华消化病与影像杂志编委（来源：《国际肝病》编辑部）声明凡署名原创的文章版权属《肿瘤瞭望》所有，欢迎分享、转载。本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。

放射疗法

2025-03-03

·法伯新天

靠海、向阳！海盐这片千亩土地正在质变（转载）

以下文章来源于“海盐发布”公众号活力四射的创业热土在秦山街道靠近杭州湾海面一侧，有一片面积超千亩的区域。这里不仅承载着海盐打造核技术应用（同位素）新质产业的舞台，更将成为全国“救命核药”主要的生产区域。新春伊始，这片土地上风起云涌，活力四射。中核秦山同位素生产基地项目投入生产运营诺华中国放射性药品生产项目火热建设法伯新天生产研发基地项目即将破土动工颐核医疗核素及肿瘤靶向治疗药物建设项目基本完成桩基施工同位素标准厂房一期即将交付核技术创新中心项目即将验收坐拥天时地利人和，这是被“眷顾”的创业热土。日前，记者蹲点海盐核技术应用（同位素）产业园，切身感受新质产业发展的澎湃脉动！走在产业园核心道路同兴路上，两侧的项目正在“拔节生长”。路南侧的中核秦山同位素生产基地项目已经投产，北侧两个工地则火热建设中。海盐核技术应用（同位素）产业园法伯新天项目项目效果图法伯新天项目即将于今年3月破土动工。该项目总投资5亿元，占地20.74亩，预计2026年8月竣工验收，2027年9月正式投入运营，形成年产各类诊断和治疗药品共计165万支的生产能力。实验员正在进行细胞实验作为首批入驻海盐秦山街道的同位素研发企业之一，嘉兴法伯新天医药科技有限公司是一家专注于分子影像诊断及放射性药物治疗的创新型药物研发公司，拥有国内领先的核药知识产权，建立了差异化的研发管线，产品覆盖诊断用药和治疗用药。法伯新天首席运营官王桐表示，选择扎根海盐，就是看中了这里的天时、地利、人和。秦山核电研发全国首个商用堆在线辐照生产同位素装置 “天时指的是秦山核电具备全国独有的商用重水堆优势，可以稳定供应生产同位素；地利指的是海盐位于长三角经济带核心位置，区位交通与市场优势显著；人和指的是以同位素产业专班牵头的政府帮扶力量，在设立迁址、执照审批、立项供地、行政审批、开户融资等各方面都给予我们大力支持，帮助企业有效缩短前期准备时间，为项目落户提供了高效服务。”王桐说。诺华项目诺华项目和法伯项目建设现场与法伯新天生产研发基地项目相邻的就是瑞士诺华项目。该项目总投资约6亿元，目前正紧锣密鼓地进行桩基施工，预计今年上半年完成主体工程，2026年正式投产。项目将应用同位素镥-177，计划生产用于治疗前列腺癌的放射配体疗法创新药物。颐核项目颐核医疗项目建设现场同在这片区域，总投资2.5亿元的颐核医疗核素及肿瘤靶向治疗药物建设项目，在2024年7月开工。目前桩基施工已基本完成，预计2026年正式投产。未来这里将利用同位素钇-90，生产用于治疗肝癌的核药。核技术创新中心核技术创新中心在远一点的核电科技馆北侧，核技术创新中心项目现场也是一片火热。90余名工人正抓紧进行室外附属及绿化施工。该项目计划今年3月底完成初步验收。目前，中心内部公共区域装修方案已设计完成，3月将开展招标工作，整体项目预计今年7月投入使用。 A座采光中庭该项目总投资2.7亿元，规划用地33亩，总建筑面积7.1万平方米，包含产业孵化大楼A座、B座、C座和学术交流中心4个建筑板块。海盐将以该项目为依托，联合国内顶尖高校及上下游企业，大力招引同位素产业科研、孵化、教育、培训、交流等机构。报告厅景观餐厅此外，好消息不断 2024年11月，同在该区域的中核秦山同位素有限公司成功获得园区首张甲级辐射安全许可证，正式投入生产运营。中核秦山同位素生产基地今年3月，总投资4.2亿元的同位素标准厂房一期将正式交付给砹尔法、华核等入驻企业进行室内装修、设备安装等工作。同位素标准厂房一期一个个亿元项目扎堆林立，“千亩千亿”的同位素产业宏伟蓝图正逐步从规划变为现实，海盐核技术应用（同位素）产业的未来充满无限可能。 2025年，海盐将推动同位素产业纳入上级规划，持续完善公共服务平台，启动核医疗中心建设。同时，充分发挥秦山核电在同位素科研方面的创新能力，全力争创国家级研发中心和省级创新联合体。海盐核技术应用（同位素）产业园未来海盐核技术应用（同位素）产业园还将为初创型企业打造公共服务平台，在研发、人才、技术等方面提供有力支持，力争在同位素研发生产、放射性药物研发、临床转化与应用等领域取得突破，成为全国领先的核技术应用创新发展高地。

放射疗法抗体药物偶联物并购

100 项与钇90 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	V09	-

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
诊断试剂	欧盟	CIS Bio International SA	2003-03-24
诊断试剂	冰岛	CIS Bio International SA	2003-03-24
诊断试剂	列支敦士登	CIS Bio International SA	2003-03-24
诊断试剂	挪威	CIS Bio International SA	2003-03-24

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
肝细胞癌	临床3期	中国	昆翎（天津）医药发展有限公司	2021-09-13
肝细胞癌	临床3期	中国	Biocompatibles UK Ltd.	2021-09-13

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ESMO_ASIA2024	N/A	不可切除的肝细胞癌	63	Yttrium-90 (Y-90) resin microspheres (SIRT with Y-90 resin microspheres)	構襯鹽憲醖簾餘鑰艱憲(壓糧獵遞醖網鏇醖廠窪) = developed in 8 (12.7%) patients and no serious AE was reported 網淵觸選積網膚蓋鑰膚 (膚築憲鹹鬱製簾餘襯網 ) 更多	积极	2024-12-07
ESMO_ASIA2024	N/A	不可切除的肝细胞癌	63	Yttrium-90 (Y-90) resin microspheres (SIRT with Y-90 resin microspheres)	糧構淵蓋鏇範選鏇積鹹(鏇積廠鬱積膚淵鑰醖築) = developed in 8 (12.7%) patients and no serious AE was reported 餘選淵膚積膚簾範淵構 (衊膚廠廠築製觸鬱窪築 ) 更多	积极	2024-12-07
EANM2024	N/A	-	39	Yttrium-90 glass microspheres (Hepatic transarterial radioembolization with yttrium-90 (TARE))	遞蓋觸鏇獵繭網蓋繭鹽(鹽觸鏇遞範鑰夢壓齋鏇) = 憲鹽鬱遞顧網鹽積顧構鏇積遞廠餘蓋夢積鏇觸 (鬱範壓繭衊齋齋膚窪網 ) 更多	积极	2024-09-27
DDW2024	N/A	肝内胆管癌	-	Yttrium-90 radioembolization (Y90 radioembolization)	鑰廠築簾網願網簾築遞(顧壓觸襯壓遞膚積衊醖) = 選選願觸遞網淵築衊遞蓋窪顧製選範鏇繭餘獵 (衊鬱繭觸膚繭顧艱餘衊 )	-	2024-05-20
EASL_LCS2024	N/A	肝细胞癌	150	resin 90Y	選積網網艱製鹽繭淵醖(繭壓衊膚壓餘壓衊襯觸) = 餘壓壓鏇範醖遞簾齋繭鬱構壓夢築餘襯糧觸鹽 (糧窪顧願膚鑰鏇網製範 ) 更多	积极	2024-02-22
EASL_LCS2024	N/A	肝细胞癌	150	resin 90Y	選積網網艱製鹽繭淵醖(繭壓衊膚壓餘壓衊襯觸) = 簾顧憲選願鏇鬱夢築餘鬱構壓夢築餘襯糧觸鹽 (糧窪顧願膚鑰鏇網製範 ) 更多	积极	2024-02-22
ASTRO2022	N/A	黑色素瘤	-	Yttrium-90 (90Y) (iWand AÂ® applicator)	獵餘鹹顧製醖繭窪選衊(選鬱簾襯製範鬱鬱積積) = 願膚淵鑰顧壓築製鏇願鹹衊夢憲鬱憲鏇鏇積顧 (範鹽膚壓選齋壓積鹽淵 ) 更多	-	2022-11-01
TARGET Round Robin sub-study (EANM2022)	N/A	肝细胞癌 90 Y glass microspheres	20	Yttrium-90 (Anatomic workflow)	夢獵糧淵膚遞憲築網製(鏇齋鏇蓋齋積積壓鑰夢) = 範壓獵艱選膚窪壓繭網壓醖鑰鬱鹽夢夢鏇願艱 (憲簾網襯製願鑰壓簾鹽 ) 更多	-	2022-09-22
TARGET Round Robin sub-study (EANM2022)	N/A	肝细胞癌 90 Y glass microspheres	20	Yttrium-9099m Tc-MAA (99m Tc-MAA SPECT workflow)	夢獵糧淵膚遞憲築網製(鏇齋鏇蓋齋積積壓鑰夢) = 選獵範醖網鬱鹽簾鏇選壓醖鑰鬱鹽夢夢鏇願艱 (憲簾網襯製願鑰壓簾鹽 ) 更多	-	2022-09-22
SNMMI2022	N/A	-	-	Y-90 (Y90 SIR-Spheres)	簾衊鑰壓淵網憲膚選襯(壓簾獵選積窪範衊齋襯) = 醖範遞蓋醖築衊獵衊憲鏇獵觸範窪築製蓋構窪 (鏇積觸壓廠鬱鬱鹽衊鹽 )	-	2022-08-08
SNMMI2022	N/A	-	-	Y-90 (TheraSphere)	簾衊鑰壓淵網憲膚選襯(壓簾獵選積窪範衊齋襯) = 憲網壓鹹積鑰餘膚製窪鏇獵觸範窪築製蓋構窪 (鏇積觸壓廠鬱鬱鹽衊鹽 )	-	2022-08-08
SNMMI2022	N/A	肝细胞癌	-	Yttrium-90 (90Y-glass radioembolization)	構鬱鬱夢遞遞鑰壓築廠(顧壓選膚鹹鹽衊壓憲繭) = 膚廠築醖鏇艱鹹襯鑰範膚窪夢顧簾窪遞艱築鬱 (選齋餘齋鬱築廠簾鹹艱 )	-	2022-08-08
SNMMI2021	N/A	肝转移	35	yttrium 90 (Patients with metastatic liver disease)	餘觸鏇願選觸衊構獵範(鬱齋獵襯鹽範夢鑰簾膚) = 願憲繭繭廠憲願醖範鬱鬱製願積鏇醖餘鏇醖獵 (鹽鏇鏇艱積範鹽齋餘壓, 4.9 (IQR 3.9 ~ 7.1)) 更多	积极	2021-05-18